Journal Home
Search for

Volume 52, Issue 6, Pages 1139-1150 (December 2008)


View previous. 15 of 37 View next.

Association of Changes in Bone Remodeling and Coronary Calcification in Hemodialysis Patients: A Prospective Study

Daniela Veit Barreto, MD1, Fellype de Carvalho Barreto, MD1, Aluízio Barbosa de Carvalho, MD1, Lilian Cuppari, PhD1, Sérgio Antonio Draibe, MD1, Maria Aparecida Dalboni, PhD1, Rosa Maria Affonso Moyses, MD2, Kátia Rodrigues Neves, MD2, Vanda Jorgetti, MD2, Márcio Miname, MD3, Raul D. Santos, MD3, Maria Eugênia F. Canziani, MD1Corresponding Author Informationemail address

Received 20 February 2008; accepted 24 June 2008. published online 29 September 2008.

Background

Vascular calcification is common and constitutes a prognostic marker of mortality in the hemodialysis population. Derangements of mineral metabolism may influence its development. The aim of this study is to prospectively evaluate the association between bone remodeling disorders and progression of coronary artery calcification (CAC) in hemodialysis patients.

Study Design

Cohort study nested within a randomized controlled trial.

Setting & Participants

64 stable hemodialysis patients.

Predictor

Bone-related laboratory parameters and bone histomorphometric characteristics at baseline and after 1 year of follow-up.

Outcomes

Progression of CAC assessed by means of coronary multislice tomography at baseline and after 1 year of follow-up. Baseline calcification score of 30 Agatston units or greater was defined as calcification. Change in calcification score of 15% or greater was defined as progression.

Results

Of 64 patients, 26 (40%) had CAC at baseline and 38 (60%) did not. Participants without CAC at baseline were younger (P < 0.001), mainly men (P = 0.03) and nonwhite (P = 0.003), and had lower serum osteoprotegerin levels (P = 0.003) and higher trabecular bone volume (P = 0.001). Age (P = 0.003; β coefficient = 1.107; 95% confidence interval [CI], 1.036 to 1.183) and trabecular bone volume (P = 0.006; β coefficient = 0.828; 95% CI, 0.723 to 0.948) were predictors for CAC development. Of 38 participants who had calcification at baseline, 26 (68%) had CAC progression in 1 year. Progressors had lower bone-specific alkaline phosphatase (P = 0.03) and deoxypyridinoline levels (P = 0.02) on follow-up, and low turnover was mainly diagnosed at the 12-month bone biopsy (P = 0.04). Low-turnover bone status at the 12-month bone biopsy was the only independent predictor for CAC progression (P = 0.04; β coefficient = 4.5; 95% CI, 1.04 to 19.39). According to bone histological examination, nonprogressors with initially high turnover (n = 5) subsequently had decreased bone formation rate (P = 0.03), and those initially with low turnover (n = 7) subsequently had increased bone formation rate (P = 0.003) and osteoid volume (P = 0.001).

Limitations

Relatively small population, absence of patients with severe hyperparathyroidism, short observational period.

Conclusions

Lower trabecular bone volume was associated with CAC development, whereas improvement in bone turnover was associated with lower CAC progression in patients with high- and low-turnover bone disorders. Because CAC is implicated in cardiovascular mortality, bone derangements may constitute a modifiable mortality risk factor in hemodialysis patients.

1 Department of Internal Medicine, Division of Nephrology, Federal University of São Paulo, São Paulo, Brazil

2 Department of Internal Medicine, Division of Nephrology, University of São Paulo, São Paulo, Brazil

3 The Lipid Clinic of the Instituto do Coração (InCor, Heart Institute), University of São Paulo, São Paulo, Brazil

Corresponding Author InformationAddress correspondence to Maria Eugênia F. Canziani, MD, Rua Pedro de Toledo, 282, CEP 04039-000, São Paulo, SP, Brazil

 Originally published online as doi:10.1053/j.ajkd.2008.06.024 on September 29, 2008.

PII: S0272-6386(08)01119-0

doi:10.1053/j.ajkd.2008.06.024


View previous. 15 of 37 View next.